FDA head warns of backlash against pharma innovators in attack on “anti-competitive” patent strategies
US Food & Drug Administration (FDA) commissioner Scott Gottlieb has condemned the acquisition of large numbers of follow-on patent rights by branded drugs makers to extend their market monopolies. This patent thicketing, he argued, is one of several…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.